Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels.

Bakir Ekinci, Pinar; Kara, Emre; Er, Ahmet Gorkem; Inkaya, Ahmet Cagkan; Demirkan, Kutay; Uzun, Omrum

Bakir Ekinci, Pinar; Kara, Emre; Er, Ahmet Gorkem; Inkaya, Ahmet Cagkan; Demirkan, Kutay; Uzun, Omrum.

Afiliación

Bakir Ekinci P; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
Kara E; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
Er AG; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Inkaya AC; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Demirkan K; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
Uzun O; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Br J Clin Pharmacol ; 88(3): 1387-1391, 2022 03.

Article en En | MEDLINE | ID: mdl-34174111

Asunto(s)

COVID-19; Aspergilosis Pulmonar; Antifúngicos/efectos adversos; Humanos; Aspergilosis Pulmonar/tratamiento farmacológico; SARS-CoV-2; Voriconazol/efectos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Aspergilosis Pulmonar / COVID-19 Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Turquía

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google